We recently sat down with Miquel Vila-Perello, CEO of SpliceBio, at Jefferies - during which the team picked up the Series B Raise of the Year at the 2025 ELAs for their $135million round earlier this year.

SpliceBio are a Barcelona-based gene therapy company using a proprietary Protein Splicing platform to address diseases caused by large genes that traditional AAV vectors can’t deliver. Their lead program, SB-007 for Stargardt disease, is currently being investigated in their Phase 1/2 ASTRA study, marking a key clinical milestone in a condition with no approved treatments.

It was great to sit down with Miquel and hear about his journey in biotech & the origins of SpliceBio. He also shared some advice for other scientific co-founders stepping into the CEO-hotseat & his take on why Barcelona is well positioned to be the next EU biotech hot-spot.